Amongst the plethora of molecules that are currently under investigation [8], interleukin-2 (IL2) has already demonstrated, in the past decades, the great potential to evaluate activated T-lymphocytes in chronic inflammatory diseases, autoimmune disorders and cancer, thus offering the unique opportunity to non-invasively assess disease activity and to monitor therapeutic efficacy [9]. This evidence concerns the gene IL2 and cancer.